Ocular Therapeutix
OCUL
261 hedge funds and large institutions have $2.03B invested in Ocular Therapeutix in 2026 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 104 increasing their positions, 79 reducing their positions, and 38 closing their positions.
199% more call options, than puts
Call options by funds: $21.2M | Put options by funds: $7.11M
32% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 79
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
15% more capital invested
Capital invested by funds: $1.77B → $2.03B (+$264M)
0.57% less ownership
Funds ownership: 94.99% → 94.41% (-0.57%)
3% less funds holding
Funds holding: 270 → 261 (-9)
11% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$29.4M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$19.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$35.4M |
| 2 |
CC
Commodore Capital
New York
|
-$21.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.3M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$9.89M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$7.65M |
OCUL Hedge Fund Activity: Q2 2026 in Review
261 institutional investors reported a position in Ocular Therapeutix (OCUL) for Q2 2026, worth a combined $2.03B — up 15% from $1.77B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of OCUL and 34 opened new positions — a net loss of 4 holders — while 79 trimmed existing stakes and 104 added.
The largest buyer was BlackRock, adding an estimated $29.4M. The largest seller was AllianceBernstein, cutting an estimated $35.4M.
- 261 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2026, down from 270 in Q1 2026.
- Funds reported $2.03B of Ocular Therapeutix stock for Q2 2026, up 15% quarter-over-quarter.
- 34 funds opened new Ocular Therapeutix positions in Q2 2026 and 38 closed out, a net change of -4 holders.
- The largest Ocular Therapeutix buyer in Q2 2026 was BlackRock, an estimated $29.4M added.
- The largest Ocular Therapeutix seller in Q2 2026 was AllianceBernstein, an estimated $35.4M sold.
Based on aggregated 13F filings for Q2 2026.